<DOC>
	<DOCNO>NCT00653328</DOCNO>
	<brief_summary>RATIONALE : There emerge data suggest optimal use angiogenesis inhibitor may combination chemotherapy . The optimal use atrasentan may combination chemotherapy woman relapse refractory ovarian cancer , fallopian tube cancer , peritoneal serous papillary adenocarcinoma . Due manageable toxicity profile , ease administration , activity platinum sensitive well platinum-resistant patient , Doxil become 2nd-line treatment choice woman advance stage ovarian cancer progress follow 1st-line platinum/taxane therapy . PURPOSE : To determine treatment combination atrasentan + Doxil effective 2nd line treatment patient recurrent ovarian cancer , fallopian tube cancer , peritoneal cancer .</brief_summary>
	<brief_title>Ph II Atrasentan + DOXIL Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine median time tumor progression patient recurrent ovarian epithelial cancer , fallopian tube adenocarcinoma , peritoneal serous papillary adenocarcinoma treat Doxil atrasentan hydrochloride . Secondary - To determine objective response rate survival patient treat regimen . - To determine toxicity regimen patient . OUTLINE : This multicenter study . Patients stratify accord response prior treatment platinum-taxane ( sensitive v resistant ) . Patients administer Doxil 50 mg/m2 intravenous every 28 day take atrasentan 10 mg orally everyday continuously begin Day 1 . Patients continue Doxil + atrasentan absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day every 2 month thereafter .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma , Papillary</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma arise ovary , fallopian tube , peritoneum ( i.e. , peritoneal serous papillary adenocarcinoma ) Received prior treatment either cisplatin carboplatin combination paclitaxel docetaxel firstline chemotherapy Radiographic evidence progressive disease and/or double CA125 level ≥ 70 IU/mL follow firstline chemotherapy Measurable disease define RECIST criterion No CNS metastases PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/μL Hemoglobin ≥ 9.5 g/dL Platelets &gt; 100,000/μL Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN AST ALT ≤ 2.5 time ULN ( ≤ 5.0 time ULN liver metastasis present ) LVEF ≥ 50 % MUGA Not pregnant nursing Negative pregnancy test Surgically sterile must use effective contraception No known HIV positivity AIDS No uncontrolled heart disease , diabetes , medical condition would place patient unacceptably high risk toxicity No New York Heart Association class IIV heart failure Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior toxicity ≤ grade 1 NCICTC Version 2 criterion No prior systemic therapy cancer except cisplatin carboplatin combination paclitaxel docetaxel firstline chemotherapy More 4 week since prior chemotherapy No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>